Correlation Between Unity Biotechnology and Adaptimmune Therapeutics

Can any of the company-specific risk be diversified away by investing in both Unity Biotechnology and Adaptimmune Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unity Biotechnology and Adaptimmune Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Unity Biotechnology and Adaptimmune Therapeutics Plc, you can compare the effects of market volatilities on Unity Biotechnology and Adaptimmune Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unity Biotechnology with a short position of Adaptimmune Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unity Biotechnology and Adaptimmune Therapeutics.

Diversification Opportunities for Unity Biotechnology and Adaptimmune Therapeutics

0.69

Correlation Coefficient

Unity Biotechnology  Adaptimmune Therapeutics

Poor diversification

The 3 months correlation between Unity and Adaptimmune is 0.69. Overlapping area represents the amount of risk that can be diversified away by holding Unity Biotechnology and Adaptimmune Therapeutics Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adaptimmune Therapeutics and Unity Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unity Biotechnology are associated (or correlated) with Adaptimmune Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adaptimmune Therapeutics has no effect on the direction of Unity Biotechnology i.e., Unity Biotechnology and Adaptimmune Therapeutics go up and down completely randomly.

Pair Corralation between Unity Biotechnology and Adaptimmune Therapeutics

Considering the 90-day investment horizon Unity Biotechnology is expected to under-perform the Adaptimmune Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Unity Biotechnology is 1.0 times less risky than Adaptimmune Therapeutics. The stock trades about -0.29 of its potential returns per unit of risk. The Adaptimmune Therapeutics Plc is currently generating about -0.11 of returns per unit of risk over similar time horizon. If you would invest  30.00  in Adaptimmune Therapeutics Plc on May 7, 2025 and sell it today you would lose (22.07) from holding Adaptimmune Therapeutics Plc or give up 73.57% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	72.13%
Values	Daily Returns

Unity Biotechnology  vs.  Adaptimmune Therapeutics Plc

Unity Biotechnology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Unity Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's fundamental drivers remain fairly strong which may send shares a bit higher in September 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Adaptimmune Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in September 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Unity Biotechnology and Adaptimmune Therapeutics

The main advantage of trading using opposite Unity Biotechnology and Adaptimmune Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unity Biotechnology position performs unexpectedly, Adaptimmune Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will offset losses from the drop in Adaptimmune Therapeutics' long position.

The idea behind Unity Biotechnology and Adaptimmune Therapeutics Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .